MBB Public Markets I LLC Invests $313,000 in Zoetis Inc. $ZTS

Key Points

• MBB Public Markets I LLC acquired 1,900 shares of Zoetis Inc., valued at approximately $313,000, indicating growing institutional interest in the company.
• Zoetis reported an EPS of $1.76 for the last quarter, exceeding estimates and reflecting a 4.2% increase in revenue year-over-year.
• Analysts have mixed ratings for Zoetis, with a consensus rating of "Moderate Buy" and an average target price of $200.88, indicating potential growth.

MBB Public Markets I LLC purchased a new stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 1,900 shares of the company's stock, valued at approximately $313,000.

A number of other large investors have also made changes to their positions in ZTS. Brighton Jones LLC grew its stake in shares of Zoetis by 180.4% during the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company's stock valued at $754,000 after purchasing an additional 2,978 shares during the period. Schonfeld Strategic Advisors LLC bought a new position in shares of Zoetis during the 4th quarter valued at approximately $308,000. CoreCap Advisors LLC grew its stake in shares of Zoetis by 13.5% during the 4th quarter. CoreCap Advisors LLC now owns 1,050 shares of the company's stock valued at $171,000 after acquiring an additional 125 shares during the period. Gotham Asset Management LLC grew its stake in shares of Zoetis by 100.8% during the 4th quarter. Gotham Asset Management LLC now owns 7,973 shares of the company's stock valued at $1,299,000 after acquiring an additional 4,002 shares during the period. Finally, LRI Investments LLC grew its stake in shares of Zoetis by 18.4% during the 4th quarter. LRI Investments LLC now owns 997 shares of the company's stock valued at $162,000 after acquiring an additional 155 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Leerink Partnrs downgraded Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Argus reiterated a "buy" rating and set a $190.00 price objective on shares of Zoetis in a research note on Tuesday. Piper Sandler boosted their price objective on Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a research note on Monday, August 11th. Stifel Nicolaus downgraded Zoetis from a "buy" rating to a "hold" rating and cut their price objective for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Finally, Leerink Partners downgraded Zoetis from an "outperform" rating to a "market perform" rating and cut their price objective for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Five equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat, Zoetis currently has a consensus rating of "Moderate Buy" and an average target price of $200.88.

Zoetis Price Performance

NYSE ZTS traded down $2.28 during trading hours on Friday, reaching $148.33. The company's stock had a trading volume of 3,111,229 shares, compared to its average volume of 2,278,915. The firm's 50-day moving average price is $152.32 and its 200-day moving average price is $157.31. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 1 year low of $139.70 and a 1 year high of $200.33. The company has a market capitalization of $65.74 billion, a price-to-earnings ratio of 25.53, a PEG ratio of 2.42 and a beta of 0.89.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.46 billion for the quarter, compared to analysts' expectations of $2.41 billion. During the same period in the previous year, the firm earned $1.56 EPS. The firm's revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities research analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.